Combinations comprising N- {5-[4- [4-methy L-piperazino-methyl) -benzoylamido] -2-methylphenyl) -4- (3-pyridyl) -2-pyrimidine-amine and at least one telomerase inhibitor

Abstract

The invention relates to a method of treating a warm-blooded animal, especially a human, having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one telomerase inhibitor, to a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease and finally to the use of at least one telomerase inhibitor for the preparation of a medicament for the delay of progression or treatment of Imatinib-resistant leukemia.

1 . Method of treating a warm-blooded animal having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one telomerase inhibitor, in a quantity which is jointly therapeutically effective against a proliferative disease and in which the compounds can also be present in the form of their pharmaceutically acceptable salts, wherein the telomerase inhibitor is a glitazone compound.  
   
   
       2 . A Method according to  claim 1 , wherein the proliferative disease is leukemia or Imatinib-resistant leukemia.  
   
   
       3 . Method of treating a warm-blooded animal having a Imatinib-resistant leukemia comprising administering to the animal at least one telomerase inhibitor, in a quantity which is therapeutically effective against leukemia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts wherein the telomerase inhibitor is a glitazone compound.  
   
   
       4 . A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one telomerase inhibitor, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use and wherein the telomerase inhibitor is a glitazone compound.  
   
   
       5 . Combination according to  claim 4  wherein the compound (a) is used in the form of its monomethanesulfonate salt.  
   
   
       6 . Combination according to  claim 4 , which is a combined preparation or a pharmaceutical composition.  
   
   
       7 . A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a combination according to  claim 4  and at least one pharmaceutically acceptable carrier.  
   
   
       8 . Use of a combination according to  claim 4  for the delay of progression or treatment of a proliferative disease.  
   
   
       9 . Use of a combination according to  claim 4  for the preparation of a medicament for the delay of progression or treatment of a proliferative disease.  
   
   
       10 . Use of a combination according to  claim 8 , wherein the proliferative disease is leukemia or Imatinib-resistant leukemia.  
   
   
       11 . Use of at least one telomerase inhibitor for the preparation of a medicament for the delay of progression or treatment of Imatinib-resistant leukemia.  
   
   
       12 . Use of at least one telomerase inhibitor for the delay of progression or treatment of Imatinib-resistant leukemia.  
   
   
       13 . A method according to  claim 1 , in which the combination partners (a) and (b) are administered in synergistically effective amounts.  
   
   
       14 . A commercial package comprising a combination according to  claim 4 , together with instructions for simultaneous, separate or sequential use thereof in the delay of progression or treatment of a proliferative disease.  
   
   
       15 . A method according to  claim 1 , in wherein the glitazone compound is selected from troglitazone, pioglitazone, rosiglitazone, englitazone, ciglitazone or a combination thereof.